Enanta is leveraging its early success with its licensed HCV products to become a leader in viral and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). For an overview of our research, including our licensed products, please see our Pipeline.


The World Health Organization (WHO) has declared that NASH and its precursor, Non-alcoholic fatty liver disease (NAFLD) are now the top causes of liver disease in Western countries and represent a major global health concern. Primary Biliary Cholangitis (PBC), is another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma.

Enanta’s research in NASH/PBC is initially focused on agonists of the Farnesoid X Receptor (FXR). FXR is a nuclear receptor and a main regulator of bile acid levels in the liver and small intestine. Learn More


RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. There is currently no effective treatment available for treating RSV infection.

Enanta’s research in RSV is focused on non-fusion inhibitors that target virus replication. Enanta's lead candidate, EDP-938, an N-protein inhibitor, has been studied in a Phase 2 challenge study with top-line results announced in June 2019. Learn More

Enanta Research

HBV Programs

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is estimated that 250 million people worldwide are chronically infected, and 15-25% of patients with chronic HBV infection develop chronic liver disease, including cirrhosis, liver cancer, or liver decompensation.

Enanta has selected EDP-514, an inhibitor of the HBV core protein as its first clinical candidate which is now in a Phase 1 clinical study.